



## **Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025**

April 22, 2025 at 7:00 AM EDT

LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its first quarter 2025 financial results and operational highlights before open of US markets on Thursday, May 8, 2025.

Management will host a conference call and webcast at 8:30 am EDT/13:30 pm BST to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using this [link](#) to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the [events section](#) of Autolus' website.

### **About Autolus Therapeutics plc**

Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit [www.autolus.com](http://www.autolus.com)

### **Contact:**

Amanda Cray  
+1 617-967-0207  
[a.cray@autolus.com](mailto:a.cray@autolus.com)

Olivia Manser  
+44 7780 471 568  
[o.manser@autolus.com](mailto:o.manser@autolus.com)